|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.
|
18931684 |
2008 |
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma.
|
18931684 |
2008 |
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Patterns of somatic mutation in human cancer genomes.
|
17344846 |
2007 |
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.
|
11807987 |
2002 |
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
HEMANGIOMA, CAPILLARY INFANTILE
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We conclude that synchronous changes in VEGF and VEGFR levels in CRC tissue and serum VEGF can discriminate between metastatic and non-metastatic subjects and high levels are associated with poor survival in CRC.
|
30862805 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Gremlin 1 (GREM1), as a bone morphogenetic protein (BMP) antagonist and vascular endothelial growth factor receptor-2 (VEGFR2) novel agonist, has been confirmed as overexpressed in colorectal cancer (CRC) tissues but its role in carcinogenesis remains unclear.
|
30426548 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Limited options of targeted therapy for colorectal cancer narrowly focus on blocking cancer-generic targets VEGFR and EGFR.
|
30754629 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
According to Dr. Wells A. Messersmith, targeted therapies (ie, VEGFR, EGFR, multitargeted tyrosine kinase inhibitors) play an important role in CRC management, but none of them have been successful in the adjuvant setting (although checkpoint inhibition is now being tested in MSI-high stage III CRC).
|
31117039 |
2019 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Further studies are needed to establish the benefit of KDR mutation as predictive marker for regorafenib sensitivity for patients with CRC.
|
29924031 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thus, we evaluated VEGF, VEGFR-1 and VEGFR-2 expression in ECs of colorectal cancer (CRC) using immunohistochemistry.
|
30423986 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.
|
29588308 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lastly, we demonstrated that miR-150-5p inactivated VEGFA/VEGFR2 and the downstream Akt/mTOR signaling pathway in CRC.
|
30476901 |
2018 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers.
|
28950290 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here we found that anti-VEGFR2 therapy up-regulates both C-X-C chemokine ligand 12 (CXCL12) and C-X-C chemokine receptor 4 (CXCR4) in orthotopic murine CRC models, including SL4 and CT26.
|
28900008 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6Clo monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs.
|
28691930 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.
|
28405526 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The prognostic value of VEGFR2 expression in colorectal cancer relied on the expression of NHERF1.
|
27999191 |
2017 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In subgroup analysis, a significant improvement of CR by the addition of anti-VEGF/VEGFR drugs was observed in patients with colorectal cancer (RR, 2.10, 95 % CI 1.21-3.63, P = 0.008), ovarian cancer (RR, 3.07; 95 % CI, 1.68-5.62, P = 0.000), and patients who are treated with platinum-based regimens (RR, 1.78, 95 % CI, 1.23-2.59, P = 0.002).
|
26619847 |
2016 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Peroxiredoxin 2 is involved in vasculogenic mimicry formation by targeting VEGFR2 activation in colorectal cancer.
|
25471788 |
2015 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice With Colitis.
|
25797700 |
2015 |
|
Colorectal Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, no study has been reported evaluating the role of KDR SNPs in CRC prognosis.
|
22182247 |
2012 |
|
Colorectal Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.
|
23146028 |
2012 |